AVITA Medical (NASDAQ: RCEL, ASX: AVH) has exciting news: the FDA has approved their RECELL GO® mini, a new addition to their RECELL GO system, designed specifically for treating smaller…
Worsley Mine Development Project Receives State Approval
South32 Limited (ASX / LSE / JSE: S32; ADR: SOUHY) is pleased to announce that the Western Australian Minister for Environment has granted approval for the Worsley Mine Development Project….
Woodside Simplifies Portfolio and Unlocks Long-Term Value through Asset Swap with Chevron
Woodside has reached an agreement with Chevron for an asset swap, which will significantly reshape the company’s portfolio and streamline its Australian operations. The swap will involve the acquisition of…
Paladin Energy Secures Final Regulatory Approval for Fission Uranium Acquisition
Brisbane, Australia – December 18, 2024: Paladin Energy Ltd (ASX: PDN, OTCQX: PALAF) is pleased to announce that it has received final clearance from the Minister of Innovation, Science, and…
Viva Leisure Expands into the UK with Key Master Franchise Agreement
Viva Leisure Limited has announced a significant milestone in its international expansion strategy with the execution of a Master Franchise Agreement for the United Kingdom. This move will bring the…
Vulcan Energy Signs €879 Million Conditional Debt Commitment for Phase One of the Lionheart Project
Vulcan Energy (ASX: VUL, FSE: VUL) has announced the signing of a €879 million conditional debt commitment letter with Export Finance Australia (EFA) and a group of seven commercial banks….
Reckon Expands Investment in nQ Zebraworks for Cloud Growth
Melbourne, Australia – December 2024: Reckon Limited (ASX: RKN) has announced a US$4.5 million (AUD 7.0 million) funding commitment to nQ Zebraworks, a subsidiary of Reckon and the holding company…
Mesoblast’s RYONCIL® (remestemcel-L): The First FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a global leader in cellular medicines for inflammatory diseases, has achieved a groundbreaking milestone with FDA approval of RYONCIL® (remestemcel-L). This is the first…
Clarity Pharmaceuticals (ASX: CU6) Expands Cancer Pipeline with SAR-bisFAP Radiopharmaceutical
Clarity Pharmaceuticals (ASX: CU6), a clinical-stage radiopharmaceutical company, has announced the development of SAR-bisFAP, a novel fibroblast activation protein (FAP)-targeted radiopharmaceutical designed for the diagnosis and treatment of cancer. This…
FDA Approves Ryoncil® (remestemcel-L): The First Mesenchymal Stromal Cell (MSC) Therapy for Steroid-Refractory Acute Graft Versus Host Disease in Children
Key Highlights: Melbourne, Australia; December 19, 2024 – New York, USA; December 18, 2024 – Mesoblast Limited (ASX:MSB; Nasdaq:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, announced…